(2026). Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer. Molecular Oncology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Longitudinal Genome‐wide Aneuploidy Measurements in Circulating Cell‐free DNA to Predict Lack of Benefit from Pembrolizumab in Patients with Metastatic Urothelial Cancer."
Molecular Oncology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Longitudinal Genome‐wide Aneuploidy Measurements in Circulating Cell‐free DNA to Predict Lack of Benefit from Pembrolizumab in Patients with Metastatic Urothelial Cancer."
Molecular Oncology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.